The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 342:1991-1993 June 29, 2000 Number 26
NextNext

Warfarin for Cancer Prevention

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Schulman, S.
-PubMed Citation
Recently reported large series have provided clear evidence of an association between idiopathic thromboembolism and the development of cancer. The standardized incidence ratio for all cancers is as high as 6.7 within the first year after a thromboembolic event, and the risk is significantly higher among patients less than 65 years of age than among those who are 65 or older.1 Apart from polycythemia vera, in which thrombosis is a direct complication of hematologic abnormalities, the standardized incidence ratios for cancer after a thromboembolic event are particularly high for cancers of the ovary, pancreas, liver, lung, kidney, brain, and esophagus . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.